The Promise and Perils of Diversity Action Plans for Clinical Trials

This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.